Your browser is no longer supported. Please, upgrade your browser.
PTI Proteostasis Therapeutics, Inc. daily Stock Chart
Proteostasis Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own17.86% Shs Outstand52.15M Perf Week-9.76%
Market Cap58.40M Forward P/E- EPS next Y-0.79 Insider Trans0.00% Shs Float43.75M Perf Month6.73%
Income-43.50M PEG- EPS next Q-0.18 Inst Own17.00% Short Float3.77% Perf Quarter-22.38%
Sales0.00M P/S- EPS this Y28.00% Inst Trans-0.23% Short Ratio2.15 Perf Half Y-14.62%
Book/sh0.86 P/B1.29 EPS next Y-9.90% ROA-55.00% Target Price- Perf Year38.75%
Cash/sh0.93 P/C1.19 EPS next 5Y- ROE-75.40% 52W Range0.75 - 4.72 Perf YTD-51.32%
Dividend- P/FCF- EPS past 5Y5.70% ROI-98.00% 52W High-76.48% Beta1.13
Dividend %- Quick Ratio6.70 Sales past 5Y-0.60% Gross Margin- 52W Low47.45% ATR0.08
Employees41 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)40.71 Volatility5.05% 6.75%
OptionableYes Debt/Eq0.02 EPS Q/Q56.50% Profit Margin- Rel Volume0.17 Prev Close1.12
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume767.30K Price1.11
Recom2.00 SMA20-2.59% SMA50-10.18% SMA200-22.71% Volume133,545 Change-0.89%
Oct-18-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-12-17Reiterated Robert W. Baird Outperform $13 → $25
Apr-18-16Initiated Guggenheim Neutral
Mar-07-16Initiated Robert W. Baird Outperform $13
Mar-07-16Initiated RBC Capital Mkts Outperform $20
Mar-07-16Initiated Leerink Partners Outperform
Mar-07-16Initiated H.C. Wainwright Buy $15
Oct-17-20 02:05PM  
Oct-14-20 09:16PM  
Oct-12-20 08:00AM  
Oct-09-20 10:46AM  
Oct-06-20 12:53PM  
Oct-05-20 10:52PM  
Sep-30-20 07:43AM  
Sep-23-20 11:50PM  
Sep-22-20 06:50PM  
Sep-17-20 02:50PM  
Sep-16-20 01:19PM  
Sep-15-20 01:33PM  
Sep-14-20 05:28PM  
Sep-12-20 11:00AM  
Sep-10-20 08:50PM  
Sep-05-20 11:10AM  
Sep-04-20 06:23PM  
Sep-03-20 01:10AM  
Sep-02-20 08:00PM  
Aug-29-20 02:11PM  
Aug-28-20 11:50AM  
Aug-27-20 04:35PM  
Aug-26-20 06:56PM  
Aug-25-20 06:20PM  
Aug-24-20 06:39PM  
Aug-06-20 08:20PM  
Jun-05-20 04:05PM  
Jun-04-20 09:46AM  
Jun-01-20 07:00AM  
May-15-20 05:25PM  
May-13-20 07:43AM  
May-12-20 09:02AM  
May-06-20 12:30PM  
Apr-24-20 09:29AM  
Apr-13-20 08:00AM  
Mar-10-20 04:36PM  
Feb-26-20 09:56AM  
Feb-24-20 08:00AM  
Feb-21-20 10:12AM  
Feb-20-20 07:03AM  
Feb-19-20 11:19AM  
Feb-18-20 10:06AM  
Jan-22-20 07:00AM  
Jan-13-20 08:00AM  
Jan-09-20 12:16PM  
Jan-06-20 11:30AM  
Jan-03-20 09:56AM  
Dec-20-19 09:16AM  
Dec-17-19 09:07AM  
Dec-16-19 02:01PM  
Dec-12-19 09:10AM  
Dec-11-19 07:00AM  
Dec-09-19 08:45AM  
Dec-03-19 07:00AM  
Dec-02-19 07:00AM  
Nov-29-19 12:15PM  
Nov-27-19 08:42AM  
Nov-14-19 01:31PM  
Nov-07-19 04:05PM  
Nov-06-19 07:00AM  
Nov-05-19 10:44AM  
Oct-29-19 10:33AM  
Oct-24-19 07:00AM  
Oct-21-19 07:00AM  
Oct-02-19 09:29AM  
Sep-26-19 07:00AM  
Sep-20-19 01:22PM  
Sep-19-19 04:05PM  
Aug-15-19 03:47PM  
Aug-07-19 06:05PM  
Aug-01-19 09:21AM  
Jul-25-19 07:00AM  
Jul-23-19 07:00AM  
Jul-15-19 11:19AM  
Jun-14-19 01:38PM  
Jun-04-19 07:00AM  
Jun-03-19 07:00AM  
May-31-19 08:25AM  
May-15-19 08:00AM  
May-13-19 08:00AM  
May-08-19 08:55PM  
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
New Enterprise Associates 12, 10% OwnerNov 27Sale2.521,166,7552,941,7394,270,691Nov 29 03:34 PM
New Enterprise Associates 12, 10% OwnerNov 26Sale2.45117,164287,1345,437,446Nov 29 03:34 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.